SCHEMBL5451315

SCHEMBL5451315

O=C(c1ccc(-c2cccnc2)cc1)N1CCN(c2ccc3c(c2)CCN(C2CCC2)CC3)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 3/20 0.50
BCR P11274 3/20 0.50
MKNK1 Q9BUB5 1/20 0.49
MKNK2 Q9HBH9 1/20 0.49
HRH3 Q9Y5N1 3/20 0.48
KDM2B Q8NHM5 1/20 0.46
SLC6A7 Q99884 2/20 0.45
TMEM97 Q5BJF2 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
MBTD1 Q05BQ5 1/20 0.44
TP53BP1 Q12888 1/20 0.44
L3MBTL4 Q8NA19 1/20 0.44
L3MBTL3 Q96JM7 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
AVPR2 P30518 1/20 0.44
OXTR P30559 1/20 0.44
AVPR1A P37288 1/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459918 0.98 ABL1 (0.50) ABL1BCRMKNK1MKNK2HRH3
SCHEMBL5468207 0.88 POLB (0.56) HRH3SLC6A7TMEM97SIGMAR1MBTD1
SCHEMBL5464881 0.84 KDM4E (0.60) HRH3TMEM97SIGMAR1MBTD1TP53BP1
SCHEMBL14440657 0.81 HRH3 (0.56) HRH3TMEM97SIGMAR1MBTD1TP53BP1
SCHEMBL5465885 0.81 KDM4E (0.60) HRH3TMEM97SIGMAR1MBTD1TP53BP1
SCHEMBL5459697 0.81 L3MBTL3 (0.57) HRH3TMEM97SIGMAR1MBTD1TP53BP1
SCHEMBL1169580 0.81 MKNK1 (0.60) ABL1BCRMKNK1MKNK2HRH3
SCHEMBL14440465 0.80 HRH3 (0.53) HRH3TMEM97SIGMAR1MBTD1TP53BP1
SCHEMBL5459085 0.80 L3MBTL3 (0.52) HRH3TMEM97SIGMAR1MBTD1TP53BP1
SCHEMBL5472454 0.80 HRH3 (0.64) HRH3KDM2BTMEM97SIGMAR1MBTD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185089-A1 Benzazepine derivatives for the treatment of neurological and psychiatric disorders GLAXO GROUP LIMITED (GB) 2007-08-09 US claimed
US-20070185089-A1 Benzazepine derivatives for the treatment of neurological and psychiatric disorders GLAXO GROUP LIMITED (GB) 2007-08-09 US disclosed
US-20070185089-A1 Benzazepine derivatives for the treatment of neurological and psychiatric disorders GLAXO GROUP LIMITED (GB) 2007-08-09 US disclosed
US-20070185089-A1 Benzazepine derivatives for the treatment of neurological and psychiatric disorders GLAXO GROUP LIMITED (GB) 2007-08-09 US disclosed
EP-1730114-A1 BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS GLAXO GROUP LIMITED (GB) 2006-12-13 EP disclosed
WO-2005087746-A1 BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS GLAXO GROUP LIMITED (GB) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185089-A1 Benzazepine derivatives for the treatment of neurological and psychiatric disorders CNR2, GRIN2C, GRIN2B ABL1 1452/4885BCR 2568/4885MKNK1 3632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.